We have added Lexicon Pharmaceuticals to our evaluated company list. Founded in 1995, Lexicon initially focused on discovering drugs based on its proprietary gene knockout technology, which allows for the high-throughput generation of a library of mice with specific gene disruptions. In 2007, the company changed its name from Lexicon Genetics to Lexicon Pharmaceuticals to reflect its new priorities of drug development and commercialization.

Lexicon has several novel Phase II drugs in its pipeline. These are LX4211 for Type 2 diabetes, LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX1032 for neuroendocrine tumors.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.